



医渡科技 4 月通讯 | 2026 年

## Yidu Tech Events in April 2026

### 集团亮点

#### Business Update

医渡科技预喜首度盈利，AI 医疗商业化迎来关键里程碑

### Yidu Tech Announces First-Ever Full-Year Profit, Marking a Key Milestone in AI Healthcare Commercialization

医渡科技发布令市场振奋的盈利预喜公告，公司预计截至 2026 年 3 月 31 日止的 2026 财年将录得净利润约 5500 万元至 7000 万元人民币，实现公司自成立以来首个全年盈利。这一里程碑式的突破，标志着医渡科技正式跨过了从“烧钱布局”到“自我造血”的关键分水岭。

盈利主要得益于新订单的显著增加与整体毛利率的持续改善，随着集团产品融入 AI 能力后持续升级，有效提升了产品价值主张及市场竞争力，带动核心业务板块新订单显著增长，而毛利率提升则源于升级后融入 AI 的产品具备更高附加值、营运效率提升及规模经济效应共同作用。

花旗银行随即重申“买入”评级，目标价 11 港元/股。

Yidu Tech released an encouraging positive profit alert, expecting to record a net profit of approximately RMB55 million to RMB70 million for FY2026 ended March 31, 2026, achieving its first full-year profit since the company's establishment. This milestone breakthrough marks a pivotal turning point for Yidu Tech, officially crossing the critical inflection point from an investment-heavy expansion phase to sustainable self-generated profitability.

The expected profitability was primarily driven by a significant increase in new orders



and continued improvement in overall gross margin. As the Group's products have undergone continuous upgrades through the integration of AI capabilities, their value proposition and market competitiveness have been further strengthened, leading to substantial growth in new orders across core business segments. Meanwhile, the improvement in gross margin was driven by the higher value-added nature of upgraded AI-integrated products, enhanced operational efficiency, and economies of scale. Following the announcement, Citibank reiterated its "Buy" rating on the company, with a target price of HK\$11 per share.

**医渡科技登陆 CHIMA 2026，重磅发布三大核心解决方案**

### **Yidu Tech Showcases at CHIMA 2026 with the Launch of Three Core Solutions**

第 30 届中国医院信息网络大会暨医疗信息技术与产品展览会（CHIMA 2026）上，医渡科技举办“从数据到决策——AI 重塑医院未来”年度产品发布会，正式推出医疗智能体开发与协同方案、医渡智管新一代运营数据中心、基于科研专病库打造高质量数据集三大核心解决方案。以统一证据基础设施为底座，将智能能力深嵌诊疗每一步、医院管理每一环、数据资产每一面，全面推动 AI Hospital 从概念走向现实。本次发布引发业界广泛关注，发布现场座无虚席。

At the 30th China Hospital Information Network Conference and Medical Information Technology & Products Exhibition (CHIMA 2026), Yidu Tech hosted its annual product launch event themed "From Data to Decision: AI Reshaping the Future of Hospitals," officially unveiling three core solutions: an AI agent development and collaboration solution for healthcare, the next-generation Yidu Smart Management operational data center, and a high-quality dataset solution built on disease-specific research databases. Built upon a unified evidence infrastructure, these solutions deeply embed intelligent capabilities into every step of clinical care, every aspect of hospital management, and every layer of data assets, comprehensively accelerating the

transition of AI Hospital from concept to reality. The launch attracted widespread industry attention, with the venue filled to capacity during the event.



医渡科技当选中国医疗保险研究会理事单位

### **Yidu Tech Elected as Council Member of the China Health Insurance Research Association**

中国医疗保险研究会第四届第一次会员代表大会暨一次理事会在北京召开。大会选举产生了新一届理事会。国家医疗保障局党组成员、副局长施子海当选研究会第四届会长。医渡科技凭借在医保大数据治理、AI 技术应用及普惠型商业健康保险运营等方面的积累与实践，当选研究会第四届理事单位。

The First Members' Representative Conference and First Council Meeting of the Fourth Session of the China Health Insurance Research Association was held in Beijing, during which a new council was officially elected. Shi Zihai, member of the Party Leadership Group and Deputy Director of the National Healthcare Security

Administration, was elected President of the Association's fourth session. Leveraging its extensive experience and practical achievements in healthcare insurance big data governance, AI technology applications, and the operation of supplementary insurance programs, Yidu Tech was elected as a council member of the Association's fourth session.



宫如璟出席世界经济论坛“长寿经济”研讨会

### **Gong Rujing Attends World Economic Forum Seminar on the Longevity Economy**

医渡科技创始人、董事长宫如璟在上海出席了由世界经济论坛与上海科技大学联合主办的“长寿经济：重构系统，拥抱百岁人生”研讨会，与上海科技大学校长封东来院士、中国人民银行原行长周小川、中国医学科学院北京协和医学院教授王辰院士、IMF 原副总裁朱民、诺华公司中国区总裁兼董事总经理李尧等政产学研界嘉宾们共探百岁人生时代的经济与社会系统重构之路。

宫如璟结合医渡科技在全国重点医院、核心城市及医疗产业链的长期实践，在发言时提



出：医疗 AI 的真正分水岭，不在模型能力，而在于能否形成真实世界证据基础设施，并进入真实系统持续创造价值。

Gong Rujing, Founder and Chairlady of Yidu Tech, attended the seminar "Longevity Economy: Rebuilding Systems for a 100-Year Life" in Shanghai, jointly hosted by the World Economic Forum and ShanghaiTech University. The event brought together distinguished leaders from government, academia, healthcare, and industry, including Feng Donglai, President of ShanghaiTech University; Zhou Xiaochuan, former Governor of the People's Bank of China; Wang Chen, Academician of the Chinese Academy of Engineering and Professor at Peking Union Medical College; Zhu Min, former Deputy Managing Director of the IMF; and Li Yao, President and Managing Director of Novartis China, to discuss how economic and social systems should evolve in the era of longevity and 100-year life expectancy.

Drawing on Yidu Tech's long-term practical experience across leading hospitals, major cities, and the broader healthcare ecosystem in China, Gong Rujing noted during the discussion that the true watershed moment for medical AI lies not in model capability itself, but in whether AI can establish real-world evidence infrastructure and continuously create value within real-world systems.



徐济铭获聘荣任 CAA 智能健康与生物信息专委会副主任委员

### **Xu Jiming Appointed Vice Chairman of the CAA Intelligent Health and Bioinformatics Committee**

在西安举办的中国智能健康与生物信息大会上，中国自动化学会（CAA）智能健康与生物信息专业委员会完成换届，医渡科技联合创始人、CEO 徐济铭当选副主任委员，成为新一届负责人名单中唯一企业代表。

徐济铭随后发表了题为《循证为核，AI 原生：加速医疗数智化变革》的主旨演讲。“过去行业探讨医疗 AI，往往更多聚焦于模型、工具与单点技术能力。而未来医疗的真正变革，在于全面迈入‘证据驱动决策’的新时代。”

At the China Conference on Intelligent Health and Bioinformatics held in Xi'an, the Chinese Association of Automation (CAA) Intelligent Health and Bioinformatics Committee officially completed its leadership transition. Xu Jiming, Co-founder and CEO of Yidu Tech, was elected Vice Chairman of the committee, becoming the only

corporate representative among the newly appointed leadership members.

Following the appointment, Xu Jiming delivered a keynote speech titled "Evidence at the Core, AI-Native by Design: Accelerating the Digital and Intelligent Transformation of Healthcare." During the speech, he noted: "In the past, discussions around medical AI have largely focused on models, tools, and isolated technological capabilities. The true transformation of future healthcare, however, lies in fully entering a new era of evidence-driven decision-making."



徐济铭受邀参加数字宁夏建设专家座谈会

### **Xu Jiming Invited to Attend the Digital Ningxia Development Expert Symposium**

为深入贯彻落实党中央、国务院关于数字中国建设的战略部署，高质量实施数字宁夏战略，数字宁夏建设专家座谈会在银川举行。医渡科技联合创始人、CEO 徐济铭作为人工智能领域专家受邀出席，为数字宁夏高质量发展建言献策。徐济铭表示，宁夏正以“东数西算”枢纽为牵引，加速构建算力底座与数据要素双轮驱动的数字生态，为人工智能



向垂直行业纵深渗透提供了重要战略窗口。医疗健康是算力转化为民生价值的高确定性赛道——医渡科技愿与宁夏深度携手，将疾病智能建模、专病知识库、专科智能体等核心能力全面融入区域医疗体系，以数智技术赋能民生健康。

To further implement the strategic plans of the CPC Central Committee and the State Council on building a Digital China and to advance the high-quality implementation of the Digital Ningxia strategy, the Digital Ningxia Development Expert Symposium was held in Yinchuan. Xu Jiming, Co-founder and CEO of Yidu Tech, was invited to attend the symposium as an expert in artificial intelligence, contributing insights and recommendations for the high-quality development of Digital Ningxia.

Xu Jiming noted that Ningxia is leveraging its role as a national "Eastern Data, Western Computing" hub to accelerate the development of a digital ecosystem driven by both computing infrastructure and data elements, creating an important strategic opportunity for AI to penetrate deeper into vertical industries. He emphasized that healthcare is a highly certain sector where computing power can be effectively transformed into tangible public value. Yidu Tech is committed to deep collaboration with Ningxia by integrating its core capabilities — including disease intelligence modeling, disease-specific knowledge bases, and specialty AI agents — into the regional healthcare system, empowering public health and healthcare services through digital intelligence technologies.

欧洲心脏病学会代表团到访医渡科技，共探心血管数字医疗合作新机遇

### **Delegation from the European Society of Cardiology Visits Yidu Tech to Explore New Opportunities in Digital Cardiovascular Healthcare Collaboration**

欧洲心脏病学会（ESC）代表团到访医渡科技上海分公司。作为全球心血管领域最具权威的学术组织之一，ESC 在临床指南、学术研究及数字心血管领域拥有广泛影响力。会谈期间，医渡科技相关负责人围绕公司整体战略、医疗健康布局、心血管领域发展方向



及全球市场规划进行了系统介绍，并重点展示了公司在医疗 AI 与真实世界数据研究方面的核心能力。双方就技术落地、学术协同及国际拓展等合作方向展开深入探讨，助力实现数字健康与心血管 AI 领域的优势互补与资源对接。

A delegation from the European Society of Cardiology (ESC) visited Yidu Tech's Shanghai office. As one of the world's most authoritative academic organizations in the field of cardiovascular medicine, the ESC holds extensive influence in clinical guidelines, academic research, and digital cardiovascular health. During the meeting, representatives from Yidu Tech provided a comprehensive introduction to the company's overall strategy, healthcare industry positioning, cardiovascular business development initiatives, and global market plans, while highlighting its core capabilities in medical AI and real-world data research. The two sides engaged in in-depth discussions on potential collaboration in areas including technology implementation, academic cooperation, and international market expansion, aiming to strengthen complementary advantages and resource integration in digital health and cardiovascular AI.





穗港澳高层次人才促进会参访医渡科技，共探大湾区医疗健康产业高质量发展

**Delegation from the Guangzhou Hong Kong Macao High-Level Talent Association Visits Yidu Tech to Explore High-Quality Development of the Greater Bay Area Healthcare Industry**

广州市穗港澳高层次人才促进会一行到访医渡科技北京总部。医渡科技高级副总裁袁芳携团队热情接待。嘉宾们首先参观了企业展厅，随后双方围绕“AI 赋能临床科研”“数智化临床研究”及新药研发等议题展开深入交流。医渡科技重点展示了科研平台、大模型及一站式数智化临床研究服务的最新成果，并分享了人工智能在新药靶点发现、临床试验优化等方面的应用实践。与会专家积极互动，就数智技术加速新药研发、提升临床研究效率等话题交换了意见。双方将在成果转化、协同创新、人才培养等方面深化合作，探索“AI+新药研发”与智慧医疗的新路径，共同推动大湾区医疗健康产业高质量发展。

A delegation from the Guangzhou Hong Kong Macao High-Level Talent Association visited Yidu Tech's Beijing headquarters, where Yuan Fang, Senior Vice President of Yidu Tech, warmly welcomed the guests together with her team. The delegation first toured the company's exhibition hall, followed by in-depth discussions on topics including AI-empowered clinical research, digitally intelligent clinical research, and innovative drug development. Yidu Tech showcased its latest achievements in research platforms, large language models, and one-stop digitally intelligent clinical research services, while also sharing practical applications of AI in areas such as novel drug target discovery and clinical trial optimization. Participating experts actively exchanged views on how digital intelligence technologies can accelerate innovative drug development and improve clinical research efficiency. Both sides expressed their intention to deepen collaboration in areas including commercialization of research outcomes, collaborative innovation, and talent development, jointly exploring new pathways for "AI + innovative drug development" and smart healthcare, and contributing to the high-quality development of the Greater Bay Area healthcare industry.



## 业务进展

### Business Progress

医渡智循接入 DeepSeek-V4，临床智能助手能力再升级

### Yidu Evidence Integrates DeepSeek-V4, Further Upgrading Its Clinical AI Assistant Capabilities

DeepSeek 正式发布并开源新一代旗舰模型 DeepSeek-V4 预览版当天，“医渡智循”即完成了 DeepSeek-V4 与医渡大模型双基座架构的医学场景适配。百万 token 超长上下文、更强的推理性能、更优的复杂问题处理能力，三项升级同步落地“医渡智循”临床问答、病历分析、循证检索三大核心场景。

On the same day that DeepSeek officially released and open-sourced the preview version of its next-generation flagship model, DeepSeek-V4, Yidu Evidence completed the medical scenario adaptation of its dual-foundation architecture combining DeepSeek-V4 and Yidu's proprietary large language model. With three major upgrades



— ultra-long context windows supporting millions of tokens, enhanced reasoning performance, and stronger capabilities in handling complex medical questions — the new architecture has been fully integrated into Yidu Evidence's three core clinical scenarios: clinical Q&A, medical record analysis, and evidence-based retrieval.

医渡科技中标海南智慧健康岛项目

### **Yidu Tech Wins Bid for Hainan Smart Health Island Project**

医渡科技成功中标海南智慧健康岛建设工程项目，项目金额约 1476 万元。该项目是“三医联动一张网”二期工程，是海南自贸港建设背景下一项系统性、创新性的健康民生工程，将强化数字疗法等智慧健康技术产品在基层的推广应用，成为公司在海南及全国拓展的省级示范案例。

Yidu Tech has successfully won the bid for the Hainan Smart Health Island Construction Project, with a contract value of approximately RMB14.76 million. The project is part of the Phase II initiative of the "Three-Medical Linkage Integrated Network" program and represents a systematic and innovative public health project under the broader development of the Hainan Free Trade Port. It aims to accelerate the adoption and application of smart health technologies, including digital therapeutics, at the primary healthcare level. The project is also expected to serve as a provincial-level benchmark case for Yidu Tech's future expansion in Hainan and across China.

医渡科技中标海南省统筹区域传染病监测预警与应急指挥信息平台（二期）项目

### **Yidu Tech Wins Bid for Hainan Provincial Infectious Disease Surveillance, Early Warning and Emergency Command Information Platform (Phase II)**



医渡科技成功中标省统筹区域传染病监测预警与应急指挥信息平台(海南省二期)项目,项目总金额约为人民币1289万元。此前海南省卫生健康委员会携手医渡科技开发了“数据多点触发,创新海南自贸港‘外防输入’传染病监测预警新模式”,旨在构建智能化的传染病监测预警平台,实现对重点传染病的早发现、早预警、早处置,为自贸港的公共卫生安全保驾护航。

Yidu Tech has successfully won the bid for the Hainan Provincial Integrated Infectious Disease Surveillance, Early Warning and Emergency Command Information Platform (Phase II) project, with a total contract value of approximately RMB12.89 million. Previously, the Hainan Provincial Health Commission collaborated with Yidu Tech to develop the initiative "Multi-Point Data Triggering: An Innovative Infectious Disease Surveillance and Early Warning Model for Preventing Imported Cases in the Hainan Free Trade Port." The initiative aims to build an intelligent infectious disease surveillance and early warning platform capable of enabling early detection, early warning, and rapid response for key infectious diseases, thereby strengthening public health security for the Hainan Free Trade Port.

**医渡科技携手海南共探医疗数据价值化新路径**

### **Yidu Tech Explores New Pathways for Healthcare Data Value Creation Together with Hainan**

在博鳌乐城国际医疗旅游先行区举办的“数聚自贸港·智健新未来——三医健康数据赋能人工智能创新产业发布会”上,由医渡科技与海南省卫健委、海南省疾控局、海南省三医大数据中心、海南省肿瘤医院联合打造的5款医疗智能体正式发布,同步完成医学人工智能模型训练数据服务合作签约。

At the "Data-Powered Free Trade Port · Intelligent Health for the Future — Healthcare Data Empowering AI Innovation Industry Launch Event" held in the Boao Lecheng Pilot



Zone of International Medical Tourism, five medical AI agents jointly developed by Yidu Tech, the Hainan Provincial Health Commission, the Hainan Provincial Center for Disease Control and Prevention Administration, the Hainan Provincial Healthcare Big Data Center, and Hainan Cancer Hospital were officially launched. During the event, the parties also completed the signing ceremony for cooperation on medical artificial intelligence model training data services, further advancing the exploration of healthcare data value creation and AI innovation in Hainan.



### 医渡科技中标北肿人工智能建设银医合作项目

### Yidu Tech Wins Bid for AI Development Collaboration Project with Peking University Cancer Hospital

医渡科技成功中标北京大学肿瘤医院人工智能建设银医合作项目，项目总金额约为人民币 488 万元。该项目是公司在医疗人工智能大模型领域的又一重要突破性实践。公司将以北京大学肿瘤医院为示范场景持续深耕，推动大模型业务在更多医疗场景中全面拓展。



Yidu Tech has successfully won the bid for the AI development collaboration project between banks and hospitals at Peking University Cancer Hospital, with a total contract value of approximately RMB4.88 million. The project represents another important breakthrough in the company's large language model applications for AI medical. Leveraging Peking University Cancer Hospital as a flagship demonstration scenario, Yidu Tech will continue to deepen its capabilities and accelerate the broader expansion of LLM applications across more healthcare scenarios.

医渡科技中标广医科大附一院临床试验 SMO 项目

### **Yidu Tech Wins Bid for Clinical Trial SMO Project at The First Affiliated Hospital of Guangzhou Medical University**

医渡科技成功中标广州医科大学附属第一医院的 PIONEER2 临床试验 SMO（现场管理组织）技术服务项目，总金额约 410 万元。该项目由广州呼吸健康研究院、国家呼吸医学中心及国家呼吸系统疾病临床医学研究中心联合发起，旨在开展针对轻中度慢性阻塞性肺疾病患者的早期干预研究。此次再度中标同一系列的升级项目 PIONEER2，实现了与核心客户在呼吸疾病临床研究领域的深度绑定与业务延续，充分验证了公司在细分赛道上的专业壁垒与服务口碑，也标志着客户对医渡科技临床研究能力的高度信任与持续复购。

Yidu Tech has successfully won the bid for the PIONEER2 clinical trial SMO (Site Management Organization) technical service project at The First Affiliated Hospital of Guangzhou Medical University, with a total contract value of approximately RMB4.1 million. The project was jointly initiated by the Guangzhou Institute of Respiratory Health, the National Center for Respiratory Medicine, and the National Clinical Research Center for Respiratory Disease, aiming to conduct an early intervention study for patients with mild-to-moderate chronic obstructive pulmonary disease (COPD). Winning the upgraded PIONEER2 project within the same series further strengthens Yidu Tech's long-term collaboration and business continuity with key



clients in the field of respiratory disease clinical research. It also demonstrates the company's strong professional barriers and service reputation in this specialized sector, while reflecting clients' high level of trust and continued repeat engagement with Yidu Tech's clinical research capabilities.

## 集团荣誉

### Honors of Yidu Tech

医渡智循登榜“2026 行业级智能体 TOP100”，斩获医疗赛道第二！

### **Yidu Evidence Ranked No. 2 in Healthcare on the "2026 Industry-Level AI Agents TOP100" List**

中国科学院《互联网周刊》联合 eNet 研究院、德本咨询发布“2026 行业级智能体 TOP100 榜单”。医渡科技自主研发的医渡智循凭借在医疗 AI 循证领域的硬核技术实力、成熟落地能力与卓越产品价值，成功登榜，并位列医疗细分赛道第二名，也是本次榜单中唯一一款定位于临床循证决策的智能体。这一成绩不仅是行业对医渡智循专业地位的认证，更是对医渡科技深耕医疗、以 AI 赋能临床循证实践的高度认可。

The "2026 Industry-Level AI Agents TOP100" ranking was jointly released by Internet Weekly under the Chinese Academy of Sciences, eNet Research Institute, and DeBen Consulting. Yidu Evidence, independently developed by Yidu Tech, was successfully selected for the ranking thanks to its strong technological capabilities in evidence-based AI medical, proven implementation track record, and outstanding product value. It ranked second in the healthcare category and was the only AI agent on the list specifically positioned for clinical evidence-based decision-making. The recognition not only highlights Yidu Evidence's leading professional standing within the industry, but also reflects strong industry recognition of Yidu Tech's long-term commitment to healthcare and its efforts to empower evidence-based clinical practice through AI.



医疗10%		
1	蚂蚁阿福	蚂蚁集团
2	医渡智循	医渡科技
3	WINEX	卫宁健康
4	AI京医	京东健康
5	uMetaImaging影像全智能体	联影智能
6	智云医疗大脑	智云健康
7	SenAgent	信通网易
8	个体化体检AI智能体	美年健康
9	“百小应”医学助手	百川智能
10	AI影像智能体inferRead	推想医疗

医渡智循入选“全国企业人工智能+行动创新案例”，唯一上榜医学循证 AI

### Yidu Evidence Selected for the "2026 National Enterprise AI+ Innovation Cases TOP100" as the Only Evidence-Based Medical AI on the List

中国科学院《互联网周刊》联合 eNet 研究院、德本咨询发布“2026 全国企业人工智能+行动创新案例 TOP100 榜单”。医渡科技自主研发的“医渡智循”凭借在推动循证医学智能化领域的扎实实践荣登榜单，评审专家给出“求真务实”的高度评价，同时也是本次榜单中唯一上榜的医疗循证 AI 案例，其稀缺性与行业示范性尤为凸显。

The "2026 National Enterprise AI+ Innovation Cases TOP100" ranking was jointly released by Internet Weekly under the Chinese Academy of Sciences, eNet Research Institute, and DeBen Consulting. Yidu Evidence, independently developed by Yidu Tech, was recognized for its solid practical achievements in advancing intelligent evidence-based medicine and successfully selected for the ranking. The evaluation panel highly praised the product for its "pragmatic and truth-seeking" approach. Notably, Yidu Evidence was the only evidence-based medical AI case included in this year's list, further underscoring its rarity and strong industry-leading significance.

## 2026全国企业“人工智能+”行动创新案例TOP100

S/N	提供方	使用方	案例名称	评审结论
1	华为	南非MTN集团	构建以Agentic Network为代表的新一代智能网络体系	敢为人先
2	中信建投证券股份有限公司	中信建投证券	基于AI多智能体与监督微调的投顾大模型平台	智领未来
3	软通动力信息技术（集团）股份有限公司	海南金盘智能科技股份有限公司	基于“平台+场景”架构的制造业智能化运营新范式	事半功倍
4	北京医渡数智科技有限公司	多家顶级医疗机构及广大临床医生	“医渡智循”推动循证医学智能化的探索与实践	求真务实
5	北京火山引擎科技有限公司	赛力斯凤凰智慧科技有限公司	火山引擎具身智能技术赋能汽车产业数智化升级项目	继往开来

投资者交流

Investor Communication

医渡科技举办投资人交流会，深度解析医渡智循核心壁垒与增长潜力

**Yidu Tech Hosts Investor Exchange Session to Provide In-Depth Insights into the Core Advantages and Growth Potential of Yidu Evidence**

医渡科技举办“医渡智循”专场投资人交流会。花旗、高盛、中金公司等近百位国内外知名基金与主流券商机构代表通过线下线上方式参与，公司联合创始人、CEO 徐济铭，



CFO 封晓瑛，投资者关系总监王晓炜出席。本次交流围绕医渡科技最新发布的临床循证智能体“医渡智循”展开，通过战略解读、产品演示及深度互动，全面展示了公司在 AI 医疗领域的技术壁垒、商业模式进化与及长期增长逻辑，赢得投资者高度认可。

Yidu Tech hosted a dedicated investor exchange session focused on Yidu Evidence. Nearly 100 representatives from leading domestic and international investment funds and major brokerage institutions, including Citibank, Goldman Sachs, and China International Capital Corporation (CICC), participated both online and offline. The session was attended by Xu Jiming, Co-founder and CEO of Yidu Tech; Feng Xiaoying, CFO of Yidu Tech; and Wang Xiaowei, Investor Relations Director of Yidu Tech. Centered around Yidu Tech's newly launched clinical evidence AI agent, Yidu Evidence, the session featured strategic insights, product demonstrations, and in-depth discussions, comprehensively showcasing the company's technological barriers in AI healthcare, evolving business model, and long-term growth logic. The exchange received strong recognition and positive feedback from participating investors.



医渡科技受邀出席中泰证券交流会，系统解读 AI 产品进展与经营情况



## **Yidu Tech Invited to Participate in ZT Securities Investor Exchange Session to Share Updates on AI Products and Business Operations**

医渡科技受邀参与由中泰证券研究所举办的专题交流会，公司执行董事兼 CFO 封晓瑛及 IRD 王晓炜出席会议，与分析师及机构投资者围绕“医渡智循”等 AI 产品进展及公司最新经营情况展开深入沟通。

交流中重点介绍了以 YiduCore 为核心的 AI 技术体系及其在临床诊疗、科研及医药研发等场景中的持续落地进展，并分享了“医渡智循”在循证医学智能化方向的产品能力与商业化探索。同时，结合公司最新业务数据与订单情况，对当前经营表现及未来增长路径进行了系统解读。通过本次交流，公司进一步加强了与资本市场的沟通深度，帮助投资者更清晰地理解其 AI 医疗核心竞争力与长期发展逻辑，持续提升市场对公司战略价值与成长潜力的认知。

Yidu Tech was invited to participate in a thematic exchange session hosted by the Research Institute of ZhongTai Securities. Feng Xiaoying, Executive Director and CFO of Yidu Tech, together with Wang Xiaowei, IRD of Yidu Tech, attended the session and engaged in in-depth discussions with analysts and institutional investors regarding the progress of AI products such as Yidu Evidence and the company's latest business developments.

During the exchange, the company highlighted its AI technology framework centered on YiduCore and shared ongoing implementation progress across clinical care, scientific research, and pharmaceutical R&D scenarios. The discussion also covered the product capabilities and commercialization exploration of Yidu Evidence in the field of intelligent evidence-based medicine. In addition, based on the company's latest business metrics and order momentum, management provided a systematic interpretation of current operating performance and future growth pathways. Through this exchange, Yidu Tech further strengthened communication with the capital markets, helping investors gain a clearer understanding of the company's core competitiveness in AI healthcare and its long-term development strategy, while continuing to enhance market recognition of its strategic value and growth potential.